Clinical Trials

Fungal Infections

Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options (FORMULA-OLS)

This is the first study in patients of F901318. Patients with a limited treatment options will be enrolled and treated with F901318 (olorofim) for up to 12 weeks.

Dr Orla MorrisseyThe AlfredRecruiting
Contact: Paul Newell44 07766 130849PNewell@f2g.com

Find out more


HIV

Imaging the HIV Reservoir

This study aims to develop a method to accurately image the size and location of HIV persistence in HIV-infected individuals. The project aims to combine the broadly neutralizing anti-HIV antibody 3BNC117 with a Copper-64 radio isotope for use in a clinical trial.

The clinical trial has three different stages. The first stage is to recruit two HIV uninfected individuals and determine the safety of 3 mg/kg of 3BNC117 combined with Copper-64 and MRI/PET scanning at 1, 24 and 48 hours post infusion. The second stage is to examine the distribution on MRI/PET of the 3BNC117-Copper-64 combination in four HIV-infected individuals with viremia who are not receiving antiretroviral therapy. The final stage is to perform the same intervention in aviremic people with HIV receiving antiretroviral therapy.

Contact: James McMahon, MBBS PhD +61390768004james.mcmahon@monash.edu
Contact: Janine Roney, BHSc RN MPH +61390762296j.roney@alfred.org.au

Find out more


Viral Hepatitis

The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach (TAP)

This study will investigate the feasibility of treating people who inject drugs (PWID) with hepatitis C virus (HCV) in community-based settings with a 12-week course of oral therapy combination of sofosbuvir plus ledipasvir. It will also measure the effectiveness of using a social network-based approach to reduce HCV incidence among PWID.

Contact: Dr Joseph Doyle +61392822111  j.doyle@burnet.edu.au
Contact: Dr Brendan Quinn +61392822111 brendanq@burnet.edu.au

Find out more

Eliminating Hepatitis C Transmission by Enhancing Care and Treatment Among HIV Co-infected Individuals (co-EC)

This study will offer proof of concept that scaling up treatment for Hepatitis C virus (HCV) in individuals co-infected with HIV could lead to the elimination of HCV/HIV co-infection in gay and bisexual men by treating prevalent infection, thereby reducing new primary infections and re-infection.

Contact: Anna Bowring +61385062307 annab@burnet.edu.au
Contact: Joseph Doyle+61385062324j.doyle@burnet.edu.au

Find out more


Antimicrobial Resistance & Stewardship

Nurse-led Antimicrobial Stewardship Intervention to Increase Antibiotic Appropriateness in Residential Aged Care Facilities

The study will explore the impact of a nurse-led bundled antimicrobial stewardship intervention on the appropriateness of antimicrobial use in residential aged care facilities. The intervention will be assessed in a stepped-wedge cluster randomised controlled trial across 14 residential aged care facilities over an 18-month period.

Contact: Natali Jokanovic, BPharm, PhD

+61 3 9903 0087

natali.jokanovic@monash.edu

Contact: Trisha Peel, MBBS, FRACP, PhD+61 3 9076 2000trisha.peel@monash.edu

Find out more